News

British drugmaker GSK said yesterday that the US Food and Drug Administration (FDA) has accepted its application for priority review of gepotidacin as an oral option for uncomplicated gonorrhea infections. Gepotidacin is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by targeting a distinct binding site. In March, the FDA approved the antibiotic for treatment of uncomplicated urinary tract infections. But GSK, which developed gepotidacin in collaboration